Scholar Rock Holding annual capital expenditures (capex)
2017
2018
2019
2020
2021
2022
2023
2024
2025
Scholar Rock Holding Capital Expenditures (CapEx) Growth & History (SRRK)
Scholar Rock Holding's capital expenditures (capex) was $602,000 for fiscal 2025.
View full Scholar Rock Holding company overviewScholar Rock Holding annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $602,000 | $504,000 | +514.29% |
| 2024 | 2024-12-31 | $98,000 | $27,000 | +38.03% |
| 2023 | 2023-12-31 | $71,000 | −$993,000 | −93.33% |
| 2022 | 2022-12-31 | $1.1M | −$4.2M | −79.73% |
| 2021 | 2021-12-31 | $5.2M | $1.2M | +28.38% |
| 2020 | 2020-12-31 | $4.1M | $973,000 | +31.24% |
| 2019 | 2019-12-31 | $3.1M | $1.6M | +108.78% |
| 2018 | 2018-12-31 | $1.5M | $1.1M | +313.30% |
| 2017 | 2017-12-31 | $361,000 | — | — |
Scholar Rock Holding quarterly capital expenditures (capex)
Q3.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1,000 | −$214,000 | −99.53% |
| Q1 2026 | 2026-03-31 | $68,000 | −$203,000 | −74.91% |
| Q4 2025 | 2025-12-31 | $32,000 | $10,000 | +45.45% |
| Q3 2025 | 2025-09-30 | $84,000 | $53,000 | +170.97% |
| Q2 2025 | 2025-06-30 | $215,000 | $193,000 | +877.27% |
| Q1 2025 | 2025-03-31 | $271,000 | $248,000 | +1078.26% |
| Q4 2024 | 2024-12-31 | $22,000 | $22,000 | — |
| Q3 2024 | 2024-09-30 | $31,000 | $31,000 | — |
| Q2 2024 | 2024-06-30 | $22,000 | −$19,000 | −46.34% |
| Q1 2024 | 2024-03-31 | $23,000 | −$7,000 | −23.33% |
| Q4 2023 | 2023-12-31 | $0 | −$117,000 | — |
| Q3 2023 | 2023-09-30 | $0 | −$27,000 | — |
| Q2 2023 | 2023-06-30 | $41,000 | −$436,000 | −91.40% |
| Q1 2023 | 2023-03-31 | $30,000 | −$413,000 | −93.23% |
| Q4 2022 | 2022-12-31 | $117,000 | −$425,000 | −78.41% |
| Q3 2022 | 2022-09-30 | $27,000 | −$1.4M | −98.09% |
| Q2 2022 | 2022-06-30 | $477,000 | −$506,000 | −51.48% |
| Q1 2022 | 2022-03-31 | $443,000 | −$1.9M | −80.84% |
| Q4 2021 | 2021-12-31 | $542,000 | −$1.4M | −72.54% |
| Q3 2021 | 2021-09-30 | $1.4M | −$420,000 | −22.94% |
| Q2 2021 | 2021-06-30 | $983,000 | $909,000 | +1228.38% |
| Q1 2021 | 2021-03-31 | $2.3M | $2.1M | +1006.22% |
| Q4 2020 | 2020-12-31 | $2.0M | $504,000 | +34.29% |
| Q3 2020 | 2020-09-30 | $1.8M | $1.5M | +400.27% |
| Q2 2020 | 2020-06-30 | $74,000 | −$524,000 | −87.63% |
| Q1 2020 | 2020-03-31 | $209,000 | −$472,000 | −69.31% |
| Q4 2019 | 2019-12-31 | $1.5M | $769,000 | +109.70% |
| Q3 2019 | 2019-09-30 | $366,000 | −$233,000 | −38.90% |
| Q2 2019 | 2019-06-30 | $598,000 | $582,000 | +3637.50% |
| Q1 2019 | 2019-03-31 | $681,000 | $505,000 | +286.93% |
| Q4 2018 | 2018-12-31 | $701,000 | — | — |
| Q3 2018 | 2018-09-30 | $599,000 | $561,000 | +1476.32% |
| Q2 2018 | 2018-06-30 | $16,000 | — | — |
| Q1 2018 | 2018-03-31 | $176,000 | — | — |
| Q3 2017 | 2017-09-30 | $38,000 | — | — |
Scholar Rock Holding capital expenditures (capex) trends
Over the last five fiscal years, Scholar Rock Holding's capital expenditures (capex) decreased from $4.1M to $602,000, a change of −$3.5M. The latest reported quarter, Q2 2026, shows $1,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Scholar Rock Holding source filings ↗Community posts
Scholar Rock wins FDA approval for muscle-targeted SMA treatment
Scholar Rock ($SRRK) received FDA approval for ISEMBYLD, its apitegromab treatment for spinal muscular atrophy, in patients aged two and older receiving SMN2-targeted therapy. The company plans to begin shipping the medicine within days. Th ...